Strategic Partnerships Capitalize on a proven track record with Lilly, Synlab, and KU Leuven to accelerate co developed biomarker tests and companion diagnostics across Europe; pursue pharma and large lab collaborations to expand OncoDNA's biomarker testing menu and analytical services; position OncoXPLORE and OncoDeep kit as preferred platforms for partner projects.

End-to-End Diagnostics Offer an integrated precision oncology stack to hospitals and cancer centers that combines NGS services, biomarker testing, data analysis software, and clinical decision support; provide bundled workflows with service level agreements and license options for decision support tools to improve therapy selection and patient outcomes.

Liquid Biopsy Growth Leverage the upcoming fragmentomics liquid biopsy assay to enable therapy selection, early detection, and minimal residual disease monitoring; target clinical labs and oncology centers seeking non invasive tests; propose complementary OncoDeep biomarker panels and monitoring services to drive sustained test volumes.

Academic Pharma Alliances Expand collaborations with academic partners like KU Leuven and existing pharma partners to co develop tests aligned with drug development programs; explore licensing of OncoDNA software and biomarker panels for trials; pursue co funded research and market access opportunities.

Geographic Expansion Capitalize on the international footprint and distributor network to scale in Europe and other regions; target mid sized cancer centers and regional networks through distributors, with local training and service delivery support; align with regulatory and reimbursement pathways to accelerate adoption.